Most available data on the involvement of p53 in rodent carcinogenesis are based on results of the end point of chemically or virally induced carcinogenesis, i.e., tumors. To investigate the role of altered p53 expression in early stages of rbdent hepstocarcinogenesis in a systematic way. we treated male Wistar rats for 6 wk, for 13 wk. and for 6 wk followed by a 7-wk recovery period with chemicals classified as genotoxic (200 pprn acetylaminofiuorene [AAF]. 100 ppm N-nitrosomorpholine [MMN], 200 ppm benzo(a)pyrene). as tumor promoters and carcinogenic in experimental animals (5 ppm ethinylestradiol, 500 ppm phenobarbitone, 3,000
INTRODUCTION
Human cancer risk assessment is usually based on results of carcinogenicity studies conducted in mice and rats. The assumption thereby is that tumors induced in animal models are relevant to human cancers. Although this assumption may be generally true, it will depend for a specific tumor on the comparability of molecular alterations in humans and the experimental species. Thus, elucidation and understanding of the molecular mechanisms of the multistep process of carcinogenesis in these species is of high priority. Cellular functions of cell cycle control, DNA repair, DNA synthesis, differentiation, senescence, genome plasticity, integrity, and apoptosis are pivotal to the development of malignancy and may be different among species. A relevant marker or pathway for transfer of rodent data to humans thus should be involved in 1 or more of these functions in the species concerned and, most desirably, in many cell typeshissues.
The wildtype tumor suppressor gene p53 seems to fulfill most of these requirements because it is evolutionary highly conserved on the DNA sequence and protein function level and is involved in all these pathways (4, 8, 20, 21, 26, 29) . Its aberrant expression has been demonstrated in the majority of human malignancies (4, 8, 13, 32) . Numerous recent iii vivo results suggest a role of altered p53 expression in rodent carcinogenesis [for review, see Caamano et a1 (3) ]. For example, transgenic p53 mouse models may be useful for some human exposure scenarios (p53-deficient mice) and/or the identification of genotoxic and nongenotoxic carcinogens (hemizygous mice). Furthermore, industry recently started to evaluate alter-natives to the traditional oncogenicity bioassay, concentrating on mouse models with specific genetic alterations including the p53 tumor suppressor gene (1, 36, ILSI Subcommittee for Alternatives Carcinogenicity Testing).
In many cases of immunohistochemically detectable p53 protein and subsequent DNA analysis, genetic missense mutations in the p53 gene have been identified (8) that often result in a changed conformation with distinct antigenicity, an increased half-life, and consequently higher intracellular concentration of the protein. The polyclonal CM5 serum with a known specificity against murine and rat p53 protein (A. Sparks, University of Dundee, UK, personal communication) was chosen for the present immunohistochemical investigations because of its multiple epitope recognition and good performance on paraffin sections, the routinely preserved material in animal experiments.
To systematically investigate the role of altered p53 expression in early stages of rodent hepatocarcinogenesis, we treated male rats with substances of different carcinogenic potentials or mode of actions and control substances (benzo(a)pyrene, thioacetamide, clofibric acid, phenobarbitone, ethinylestradiol, tryptophan, thyroxine, and fructose) in different application regimens.
MATERIALS AND METHODS
Experiinerital Aitinials. This study was performed with male specific-pathogen-free Wistar rats of the strain Hsd/ Win:WU kept individually (33) under optimized hygienic conditions. At the start of the treatment, rats were about 7 wk old. Three groups of 7 animals each were treated with a pelleted fixed-formula standard diet (Altromin GmbH, Lage) containing 200 ppm benzo(a)pyrene (BaP), 600 ppm thioacetamide (TA), 3,000 ppm clofibric acid 636 (CA), 500 ppm phenobarbitone (PB), 5 pprn ethinylestradiol (EE), 20,000 pprn tryptophan 0, 200 ppm thyroxine (T4), or tapwater containing 120,000 ppm fructose (F) for 6 wk, for 6 wk followed by a 7-wk recovery period, and for 13 wk, respectively. Food and water were available for ad Zibirzm consumption. Control animals were kept for 6 or 13 wk under the same conditions and on the standard diet. Food and water consumption was calculated for 7 animals/group individually once weekly from the difference of feed supplied and not consumed. Individual absolute organ weights of the liver and the kidneys and relative organ weights (related to 100 g body weight) were determined at necropsies after 6 or 13 wk. Tissue Preparation. Animals were euthanatized by exsanguination under deep diethyl ether anesthesia. Liver lobes were fixed in buffered 4% formaldehyde for 24 hr and embedded in paraffin. For histological evaluation, 5pm sections were prepared and stained with hematoxylin and eosin (H&E).
h~~t~rrrttohistoche~nistry. For immunohistochemistry, 5-Fm liver sections were deparaffinized and rehydrated in Tiis-buffered saline (150 mi NaCl, 10 mi Tris, pH 7.6).
After inactivation of tissue peroxidase activities (0.5% H,OJ and blocking of nonspecific antibody cross-reac-tivity (10% normal goat serum, Dako A / S , Glostrup, Denmark), sections were incubated for p53 protein detection overnight at 4°C with a 1:1,OOO-1:1,750 dilution of a polyclonal rabbit serum, CM5 (provided by A. Sparks, University of Dundee) raised against recombinant wildtype mouse p53 protein similarly to CM1 (24).
Primary antibody binding was detected by a biotinylated goat anti-rabbit secondary antibody (Ready-to-use Link, BioGenex, San Ramon, CA) and peroxidase-coupled streptavidin (Ready-to-use HRP Label, BioGenex) used according to the manufacturer's specifications. Diaminobenzidine (final concentration of 0.5 mg/ml) with nickel sulfate (final concentration of 0.2 mg/ml) was used as chromogen, resulting in black granular precipitates. As positive controls, 3 paraffin-embedded liver sections from male rats treated for 6 mo with tamoxifen as described (38) were stained under identical conditions in each experiment. Results were reproduced 3 times on 1 section for animals euthanatized after 13 wk and on 3 sections for animals treated for 6 wk; positive control slides always stained positive. Evaluation was done on whole sections with an overall area of about 100 mm2 for negative controls and animals treated for 6 wk, on sections with an area of 50 mm2 for animals euthanatized after 13 wk, or on sections of area 140-230 mm2 for positive controls. Because of different cell sizes and rare single positive cells in the case of some substances, this approach was considered more appropriate than cell counting. Results and experimental details of p53-specific immunohistochemistry on liver sections treated with AAF and NNM have been previously published (see Table I ).
Statistics. Statistical evaluation of individual animal data (body weights, organ weights, food and water consumption) was performed using S A P (Cary, NC) routines. Statistical evaluation of immunohistochemical results was done using Fisher's exact test.
RESULTS
No differences in body weights were seen after treatment with NNM, BaP, PB, CA, and W (see Table 11 ). After 6 and 13 wk of AAF, EE, or TA ingestion, body weights were significantly lower (by 12% and 22%. 31% and 27%. and 43% and 37%. respectively) compared with the respective controls. During recovery, body weights increased in all these groups and were not significantly different from controls at the end of the recovery period. Furthermore, body weights were reduced after administration of thyroxine (12%) for 12 wk and of fructose (1 1%) for 6 wk followed by 7 wk of recovery. Thus, all these substances fulfilled the criterion of a 210% body weight reduction for the maximum tolerated dose, as defined by international guidelines on the conduct of toxicological studies.
With r.egard to food and water intake (see Table 111 ), there were no major differences during and after treatment with PB and CA. Pronounced effects were seen during and/or after ingestion of F, with reduced food intake during the first 6 wk of treatment and higher water consumption, ingestion of TA, with markedly reduced food and water intake during treatment, and ingestion of EE, with clearly decreased food and water (over 13 wk of treatment) intake. Administration of AAE NNM, BaP, and W over 6 wk reduced food and water consumption to a lesser extent. Treatment with T4 over 6 wk resulted in increased food intake, and treatment over 13 wk resulted in decreased food intake and a markedly increased water intake as compared with controls.
No relevant differences in organ weights (see Table 11 ) were determined at any time after administration of NNM, BaP, EE, and E After treatment with AAF for 13 wk, absolute and relative kidney weights and relative liver weights were significantly increased. Administration of PB for 6 or 13 wk resulted in markedly increased absolute and relative liver weights. After administration of CA for 6 or 13 wk, relative liver and kidney and absolute kidney weights after 13 wk were slightly to moderately increased. Relative kidney weights were higher after 6 or 13 wk, and relative liver weights were markedly higher after 13 wk of TA administration. Treatment with W for 6 wk resulted in slightly increased relative liver weights.
Treatment with T4 resulted in increases in relative kidney weights after 6 and 13 wk and in absolute kidney weights after 13 wk. All other' differences are not considered relevant because they were only minor or reflected reduced body weights of the corresponding animals. All changes in organ weights observed after 6 wk of treatment were reversible within the 7 wk recovery period (see Table 11 ).
Histological evalution was performed on H&E-stained liver sections from those animals that were immunopositive for p53. As compared with age-matched controls, there were no differences in animals treated with PB, CA, T4, and E Independent of treatment, minimal or mild cellular infiltrates and single cell necroses of few hepatocytes could be detected. In some cases, most frequently after administration of BaP and EE, a condensed cytoplasm in the periphery of the liver lobules was seen. The p53-positive rat treated with TA showed a distinct oval cell proliferation ( Fig. l) , pronounced pleomorphism of hepatocytes with prominent nucleoli, multifocal hepatocellular degeneration, beginning peliosis, and pigment deposits. In the liver of the p53-positive animal treated with W, a minimal proliferation of oval cells was detected.
As summarized in Table I ,' treatment with test substances resulted in the following distinct staining characteristics. After BaP treatment, large areas of p53-immunopositive hepatocytes were detected in 17/21 rats (81%), with an apparent increase of positive animals in relation to the time of treatment; 5/7 animals were posi-tive after 6 wk of treatment irrespective of recovery but 7/7 were positive after 13 wk of permanent treatment. The signals were granular, intense precipitates (see Fig.  2a, b) . After EE administration, 7/19 animals showed rare single and scattered p.53-positive hepatocytes, with an apparent increase in the number of positive animals in the group with and during recovery after 6 wk of treatment (2/5, 40%) compared with those without recovery (217, 29%). Permanent EE ingestion for 13 wk resulted in an incidence only slightly higher (3/7, 43%) than that of the recovery animals. TA administration resulted in rare positive hepatocellular p53 immunostaining in 1 animal treated for 6 wk. Because not all animals survived in the other 2 TA-application groups, a similar incidence seems probable. After PB treatment, 2/21 (10%) animals had rare single p53-positive hepatocytes (1/7 animals treated for 6 wk followed by 7 wk of recovery and 117 animals treated for 13 wk continously). Administration of CA resulted in slight, diffuse positive p53 immunostaining of hepatocytes in 2/7 (28%) rats treated for 13 wk, with no positive signals in the other treatment groups (overall incidence of 2/21, 10%). Feeding of T4 for 6 wk followed by 7 wk of recovery resulted in rare single positive p53 immunosignals in hepatocytes of 3/6 (50%) rats (Fig. 3) .
No signals were seen on liver sections from animals treated for 6 or 13 wk with T4. p53-specific immunostaining of animals receiving F or W was seen in 1/21 (5%) rats: 1/7 animals treated with F for 6 wk followed by 7 wk of recovery ( Fig. 4) and 1/7 animals treated with W for 13 wk (Fig. 5 ). Positively stained hepatocytes were relatively frequent, single, and scattered over the sections from both F-and W-treated animals. In addition, 2/19 control animals fed the standard diet showed positive p53-specific immunostaining in very rare single hepatocytes, both after 13 wk of husbandry (data not shown). The specificity of the reaction was confirmed by competition with increasing amounts of recombinant murine p53 protein (provided by A. Sparks, University of Dun-dee) during primary antibody incubation of liver sections (data not shown). Immunostaining was mainly cytoplasmic, although a faint reaction in the nucleus cannot be excluded.
DISCUSSION
Against a background of growing information on molecular mechanisms of carcinogenesis in different species, the assessment and evaluation of carcinogenicity assays and alternatives have attained high priority. In that context, p53 has attracted much attention because it is evolutionary highly conserved and aberrantly expressed in the majority of human malignancies (11, 13) . Investigations into the possible involvement of aberrant p53 expression at different stages of tumor development in rodents and in the underlying mechanisms and comparison of these data to human carcinogenesis will thus be of direct relevance to cancer risk assessment.
The data presented here and published earlier (40) suggest that exposure of rats to genotoxic substances for a short period of time results in a high and significant incidence of animals expressing p53 aberrantly in the liver. Thus treatment with BaP, an indirect carcinogen in experimental animals (19) and an inducer of skin tumors Abbreviations: n.i. = no intake. a Substances administered for 6 wk. for 6 wk with a 7-wk recovery period or for 13 wk continuously. Data shown sepxately for the 40 days of treatment (T) and the 51 days of recovery (R). .
Immunohistochemical results published previously (37).
with frequent and characteristic p53 mutations in mice (30), resulted in positive p53 immunohistochemistry in 17/21 (81%) rats. Analogous exposure of male rats to the genotoxic AAF and NNM resulted in positive p53 immunostaining on liver sections of 21/21 (100%) AAFand of 19/21 (90%) NNM-treated animals (40). p53 mutations have been observed in hepatocellular carcinomas induced by AAF and NNM with no obvious hot spot of mutation (12, 22) , whereas in another study no positive p53 immunostaining was detected in liver preneoplasia (9) . A positive correlation of p53 immunodetection with the period of treatment might be suggested for BaP; 517 animals were p53 positive after 6 wk and 717 were positive after 13 wk of application. However, this finding is not supported by the earlier studies on livers of AAFand NNM-treated rats; all of rats ingesting AAF were p53 positive irrespective of application regimen, but all of those treated with NNM for 6 wk and 617 treated for 13 wk were p53 immunopositive. Investigation after shorter exposure periods might be more informative about a potentia1,time correlation of the incidence of positive p53 immunohistochemistry. Administration of hepatic tumor promotors acting via epigenetic mechanisms showed low incidences of p53 staining with 1 exception: EE, which has been classified as carcinogenic in experimental animals, inducing benign and malignant hepatocellular tumors in rats after lifetime exposure (17), resulted in a relatively high incidence of animals positive for hepatocellular p53 immunodetection (7/19 or 37%), with an apparent increase after recovery and with longer exposure. However, after treatment with PB and CA, only 2/21 animals, respectively, were posi-TOXICOLOGIC PATHOLOGY tive for p53 protein, with no notable time correlation. Both compounds have been evaluated as carcinogenic in experimental animals, inducing hepatocellular tumors in rats (16, 18) . This discrepancy may well be based on the differences in the induction of mitosuppression after initial but transient stimulation of hyperplastic growth, which has been reported for all 3 promotors (35,41), but in the case of EE only for lower dosages. At 10-20 times higher dosages of EE (10 ppm), no mitoinhibition was seen, but instead an increase in hepatocellular prolifera-tion between 3 and 6 mo of chronic treatment was observed and considered to be a sign of slight hepatotoxicity and ensuing regenerative hyperplasia (23). These conditions thus were comparable to those in our experiment.
Administration of all other substances, including TA, which is classified as a carcinogen in experimental animals and induces hepatocellular and bile duct tumors in rats (15), resulted in few animals with p53-positive hepatocytes. TA is thought to act predominantly via cyto- toxicity (15), as supported by our histopathological findings. The incidence of p53-positive animals was comparable to that of animals treated with PB and CA, although not all TA-treated animals survived and a similar incidence in the other treatment groups (6 plus 7 wk, 13 wk) is conceivable. Immunodetection of p53 in single scattered hepatocytes of 3/6 (50%) rats treated for 6 wk with T4 followed by 7 wk of recovery was reproducible but not significant. Furthermore, positive p53 staining in a relatively high percentage of hepatocytes per section was seen in 1/21 (not significant) animals after administration of tryptophan and fructose, which promote carcinogenesis of the urinary bladder (39) and the liver (6), respectively. However, this result can be seen in the context of positive p53 immunohistochemistry in 2/19 control animals, (2112 rats housed without treatment for 13 wk), which also was not significant. Thus a certain "background" of altered p53 expression in unexposed individuals as shown for a p53specific antibody response in disease-free humans (37) is possible.
The role of p53 in apoptosis and repair after DNA damage, which can induce transiently immunodetectable p53, should be .kept in mind. p53-positive immunohistochemistry has been demonstrated after ultraviolet radiation exposure in normal skin or after y-irradiation in different segments of the gastrointestinal tract, correlating with differential sensitivity to p53-dependent apoptosis. However, the immunohistochemically p53-positive phenotype after both ultraviolet and y-irradiation was only transient (in the range of hours).
Immunohistochemical detection of p53 protein is suggestive of intracellular protein accumulation and is due to missense mutation in about 80% overall (4). The high incidence of immunohistochemical demonstration of p53 protein in rodent hepatocytes after exposure to genotoxic chemicals thus strongly suggests a missense mutation early in rodent hepatocarcinogenesis. Definite evidence of this mutation and clarification of positive p53 immunostaining in untreated and negative control animals and in animals treated with the other substances can only be achieved by DNA sequence analysis after single-cell polymerase chain reaction amplification. Considering the association of aberrant p53 expression with the majority of human malignancies (10, 12, 16) , its normal function for the integrity of the genome (30), and the demonstration of excess intracellular p53 protein (irrespective of the mechanism) as a distinct marker of preinvasive lesions and invasive tumors in humans (2), the high incidence of aberrantly expressed p53 protein in an early stage of genotoxically induced rodent hepatocarcinogenesis supports the hypothesis of a role of altered p53 expression in tumor development in rodents.
There was no correlation of p53-specific immunostaining with H&E histopathology. In earlier investigations on AAF and NNM induction of hepatocellular preneoplasia, enzyme-altered foci and histological changes in liver sections did not coincide with positive p53 immunohistochemistry (40) . Thus, p53 immunohistochemistry may turn out to be a highly sensitive marker for early detection of tumorigeqesis.
The nearly exclusively cytoplasmic localization of the immunohistochemical signals seen in this investigation using the CM5 polyclonal serum contrasts with the nuclear localization seen in liver sections of rats treated analogously with AAF and NNM using the polyclonal CMl serum. An obvious next step for clarification of this phenomenon is serum cross-checking to analyze a potential characteristic inherent in the serum or batch used. Cytoplasmic sequestration of p53 by yet unknown mechanisms and unidentified anchor(s) has been shown in several primary human tumors (28). including neuroblasto-TOXICOLOGIC PATHOLOGY ma and breast and colon cancer, and has been discussed as yet another way of inactivating p53 without mutation of the p53 gene (25). For colorectal cancer, even prognostic significance of increased frequency of cytoplasmic p53 expression and advanced Dukes' stages has been reported (7, 34) . p53 protein has been localized to punctuate cytoplasmic structures in neuroblastoma cells (25), as seen in the present study after treatment with BaP ( Fig.  2a, b) . Heat shock protein 84 forms a complex with p53 (3 l), suggesting that the cytoplasmic localization of p53 seen in the present study may be due to complexing of p53 protein in a mutant conformation by chaperones as a possible consequence of early toxic insult to cellular proteins. The presence of this putative mutant conformation must be explored by sequence analysis.
In conclusion, the demonstration of increased intracellular p53 protein in a high and significant proportion of rats in an early stage of hepatocarcinogenesis induced by administration of genotoxic chemicals lends further support to the hypothesis of a role of altered p53 expression in rodent tumor development. The detection of rare singular p53-positive hepatocytes in a substantial number of rats treated with ethinylestradiol may indicate a role of altered p53 expression in early hepatocarcinogenesis induced by some epigenetically acting substances. Further data are needed on the involvement and time dependence of p53 alterations with regard to the development of malignancy in specific tissues of rodents and humans to qualify the tumor suppressor gene p53 as an indicator for preneoplastic alterations of the liver with a high predictive value for risk assessment.
